Fidelity International
ABCL icon

Fidelity International’s AbCellera Biologics ABCL Stock Holding History

Fidelity International’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,061
Closed -$70.5K – 906
2024
Q4 		$70.5K Sell
24,061
-99,818
-81% -$278K ﹤0.01% 865
2024
Q3 		$322K Buy
123,879
+3,906
+3% +$10.8K ﹤0.01% 814
2024
Q2 		$355K Buy
119,973
+54,893
+84% +$208K ﹤0.01% 778
2024
Q1 		$295K Sell
65,080
-1,810,792
-97% -$9.24M ﹤0.01% 786
2023
Q4 		$10.7M Buy
+1,875,872
New +$8.69M 0.01% 497
2023
Q2 		– Sell
-19,638
Closed -$148K – 804
2023
Q1 		$148K Sell
19,638
-1,518
-7% -$13.8K ﹤0.01% 764
2022
Q4 		$214K Buy
21,156
+1,718
+9% +$19.8K ﹤0.01% 767
2022
Q3 		$192K Buy
+19,438
New +$213K ﹤0.01% 771

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity International's ABCL Position: Q1 2025 in Review

Fidelity International sold out of AbCellera Biologics (ABCL) in Q1 2025, closing a stake of 24,061 shares — an estimated $70.5K sold.

Fidelity International first reported a position in ABCL in Q3 2022 and held it in 8 quarters. The position peaked at $10.7M in Q4 2023. 129 funds tracked by Wall St. Rank hold ABCL as of Q1 2025.

  • Fidelity International reported no remaining AbCellera Biologics position as of Q1 2025 after selling out during the quarter.
  • Fidelity International sold 24,061 AbCellera Biologics shares in Q1 2025, an estimated $70.5K.
  • Fidelity International first reported a position in AbCellera Biologics in Q3 2022 and held it in 8 quarters.
  • Fidelity International's AbCellera Biologics position peaked at $10.7M in Q4 2023.
  • 129 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2025.

Based on Fidelity International's 13F filing for Q1 2025, filed 12 May 2025.